While first pilot studies evaluating brentuximab vedotin in adults with refractory testicular cancer have been initiated 10, to date, there are no data delineating bystander efficacy of the CD30‐conjugated tubulin toxin on CD30‐negative GCT cells. This evidence concerns the gene TNFRSF8 and granular cell tumor.